secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107268
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma Q2 net loss $8.5M; BI deal with $12M upfront, $345M milestones
----------------------------------------------------------------------------

- Net loss $8.5M ($0.09/share) vs $10.2M in Q2 2024; collaboration revenue $3.0M.
- Announced collaboration with Boehringer Ingelheim for CUE-501: $12M upfront, up to $345M milestones.
- Received FDA Pre-IND feedback supporting CUE-401 IND for autoimmune disease.
- CUE-101 Phase 1 data: 50% ORR, 88% 12-mo OS, median OS 32 months in HPV+ HNSCC.
- Raised ~$20M via public offering; cash position $27.5M at June 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017025107268/0000950170-25-107268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017025107268/cue-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer